Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1143572 · 1 trial · 1 indication
In Part A: Maximum tolerated dose (MTD) of BAY1143572 In Part B; Maximum tolerated dose ( MTD) with G-CSF of BAY114357 The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during cycle 1.
| Arm | Type | Description |
|---|---|---|
| BAY1143572 [continuous] | EXPERIMENTAL | BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously |
| BAY1143572 [on/off] | EXPERIMENTAL | BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule |
| Name | Type | Description |
|---|---|---|
| BAY1143572 | DRUG | - |
Inclusion Criteria: * Male or female subjects aged \>/=21 years * Dose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluab...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY1143572 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is in Phase 1 clinical development for oncology indications.
BAY1143572 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY.
BAY1143572 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and efficacy.
BAY1143572 has been studied in one clinical trial, NCT01938638, titled "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer." This Phase 1 trial enrolled 80 patients with neoplasms and has been completed.
BAY1143572 is the primary identifier for this investigational compound. No alternative names have been reported for this drug in clinical trial records.